Drug Profile
Research programme: antibody therapeutics - GlaxoSmithKline/Zymeworks
Latest Information Update: 13 Jul 2020
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Zymeworks
- Developer GSK; Zymeworks
- Class Antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 13 Jul 2020 Preclinical trials in Unspecified in Canada and United Kingdom (Parenteral), prior to July 2020 (Zymeworks pipeline, July 2020)
- 01 Jul 2020 Early research is ongoing in Unspecified in United Kingdom and Canada (Parenteral) (Zymeworks pipeline, July 2020)
- 03 Dec 2015 Early research in Undefined indication in Canada and United Kingdom (Parenteral)